Vanda Pharmaceuticals (NASDAQ:VNDA) Lifted to Buy at StockNe

StockNews.com upgraded shares of Vanda Pharmaceuticals (NASDAQ:VNDA – Free Report) from a hold rating to a buy rating in a report issued on Thursday. Vanda Pharmaceuticals Stock Performance Vanda Pharmaceuticals stock opened at $3.76 on Thursday. The firm has a market cap of $216.31 million, a price-to-earnings ratio of 17.91 and a beta of 0.59. […]

Related Keywords

, Lido Advisors , Sherbrooke Park Advisers , Tower Research Capital , Quadrant Capital Group , Vanda Pharmaceuticals , Vanda Pharmaceuticals Inc , Vanda Pharmaceuticals Company Profile , Vanda Pharmaceuticals Stock Performance , News Ratings For Vanda Pharmaceuticals Daily , Free Report , Capital Group , Research Capital , Get Free Report , Pharmaceuticals Inc , Vanda Pharmaceuticals Daily , Nasdaq Vnda , Vnda , Medical , 92165910 , Upgrade , Stocknews Com ,